The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice

Kay N Greenshields, Susan K Halstead, Femke M P Zitman, Simon Rinaldi, Kathryn M Brennan, Colin O'Leary, Luke H Chamberlain, Alistair Easton, Jennifer Roxburgh, John Pediani, Koichi Furukawa, Keiko Furukawa, Carl S Goodyear, Jaap J Plomp, Hugh J Willison

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Anti-GM1 ganglioside autoantibodies are used as diagnostic markers for motor axonal peripheral neuropathies and are believed to be the primary mediators of such diseases. However, their ability to bind and exert pathogenic effects at neuronal membranes is highly inconsistent. Using human and mouse monoclonal anti-GM1 antibodies to probe the GM1-rich motor nerve terminal membrane in mice, we here show that the antigenic oligosaccharide of GM1 in the live plasma membrane is cryptic, hidden on surface domains that become buried for a proportion of anti-GM1 antibodies due to a masking effect of neighboring gangliosides. The cryptic GM1 binding domain was exposed by sialidase treatment that liberated sialic acid from masking gangliosides including GD1a or by disruption of the live membrane by freezing or fixation. This cryptic behavior was also recapitulated in solid-phase immunoassays. These data show that certain anti-GM1 antibodies exert potent complement activation-mediated neuropathogenic effects, including morphological damage at living terminal motor axons, leading to a block of synaptic transmission. This occurred only when GM1 was topologically available for antibody binding, but not when GM1 was cryptic. This revised understanding of the complexities in ganglioside membrane topology provides a mechanistic account for wide variations in the neuropathic potential of anti-GM1 antibodies.
LanguageEnglish
Pages595-610
Number of pages16
JournalJournal of Clinical Investigation
Volume119
Issue number3
DOIs
Publication statusPublished - 2 Mar 2009

Fingerprint

Glycolipids
Autoantibodies
Anti-Idiotypic Antibodies
Membranes
Gangliosides
G(M1) Ganglioside
Aptitude
Complement Activation
Presynaptic Terminals
Neuraminidase
N-Acetylneuraminic Acid
Peripheral Nervous System Diseases
Immunoassay
Synaptic Transmission
Freezing
Monoclonal Antibodies
Cell Membrane
Antibodies

Keywords

  • animals
  • monoclonal antibodies
  • autoantibodies
  • axons
  • G(M1) ganglioside
  • glycolipids
  • humans
  • mice
  • motor neurons
  • nerve endings
  • neuromuscular junction
  • oligosaccharides
  • peripheral nervous system diseases
  • synaptic transmission
  • ran GTP-binding protein

Cite this

Greenshields, K. N., Halstead, S. K., Zitman, F. M. P., Rinaldi, S., Brennan, K. M., O'Leary, C., ... Willison, H. J. (2009). The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. Journal of Clinical Investigation, 119(3), 595-610. https://doi.org/10.1172/JCI37338
Greenshields, Kay N ; Halstead, Susan K ; Zitman, Femke M P ; Rinaldi, Simon ; Brennan, Kathryn M ; O'Leary, Colin ; Chamberlain, Luke H ; Easton, Alistair ; Roxburgh, Jennifer ; Pediani, John ; Furukawa, Koichi ; Furukawa, Keiko ; Goodyear, Carl S ; Plomp, Jaap J ; Willison, Hugh J. / The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 3. pp. 595-610.
@article{d14b4dc3e82f400c8b676c0ef4a3049e,
title = "The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice",
abstract = "Anti-GM1 ganglioside autoantibodies are used as diagnostic markers for motor axonal peripheral neuropathies and are believed to be the primary mediators of such diseases. However, their ability to bind and exert pathogenic effects at neuronal membranes is highly inconsistent. Using human and mouse monoclonal anti-GM1 antibodies to probe the GM1-rich motor nerve terminal membrane in mice, we here show that the antigenic oligosaccharide of GM1 in the live plasma membrane is cryptic, hidden on surface domains that become buried for a proportion of anti-GM1 antibodies due to a masking effect of neighboring gangliosides. The cryptic GM1 binding domain was exposed by sialidase treatment that liberated sialic acid from masking gangliosides including GD1a or by disruption of the live membrane by freezing or fixation. This cryptic behavior was also recapitulated in solid-phase immunoassays. These data show that certain anti-GM1 antibodies exert potent complement activation-mediated neuropathogenic effects, including morphological damage at living terminal motor axons, leading to a block of synaptic transmission. This occurred only when GM1 was topologically available for antibody binding, but not when GM1 was cryptic. This revised understanding of the complexities in ganglioside membrane topology provides a mechanistic account for wide variations in the neuropathic potential of anti-GM1 antibodies.",
keywords = "animals, monoclonal antibodies, autoantibodies, axons, G(M1) ganglioside, glycolipids, humans, mice, motor neurons, nerve endings, neuromuscular junction, oligosaccharides, peripheral nervous system diseases, synaptic transmission, ran GTP-binding protein",
author = "Greenshields, {Kay N} and Halstead, {Susan K} and Zitman, {Femke M P} and Simon Rinaldi and Brennan, {Kathryn M} and Colin O'Leary and Chamberlain, {Luke H} and Alistair Easton and Jennifer Roxburgh and John Pediani and Koichi Furukawa and Keiko Furukawa and Goodyear, {Carl S} and Plomp, {Jaap J} and Willison, {Hugh J}",
year = "2009",
month = "3",
day = "2",
doi = "10.1172/JCI37338",
language = "English",
volume = "119",
pages = "595--610",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
number = "3",

}

Greenshields, KN, Halstead, SK, Zitman, FMP, Rinaldi, S, Brennan, KM, O'Leary, C, Chamberlain, LH, Easton, A, Roxburgh, J, Pediani, J, Furukawa, K, Furukawa, K, Goodyear, CS, Plomp, JJ & Willison, HJ 2009, 'The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice' Journal of Clinical Investigation, vol. 119, no. 3, pp. 595-610. https://doi.org/10.1172/JCI37338

The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. / Greenshields, Kay N; Halstead, Susan K; Zitman, Femke M P; Rinaldi, Simon; Brennan, Kathryn M; O'Leary, Colin; Chamberlain, Luke H; Easton, Alistair; Roxburgh, Jennifer; Pediani, John; Furukawa, Koichi; Furukawa, Keiko; Goodyear, Carl S; Plomp, Jaap J; Willison, Hugh J.

In: Journal of Clinical Investigation, Vol. 119, No. 3, 02.03.2009, p. 595-610.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice

AU - Greenshields, Kay N

AU - Halstead, Susan K

AU - Zitman, Femke M P

AU - Rinaldi, Simon

AU - Brennan, Kathryn M

AU - O'Leary, Colin

AU - Chamberlain, Luke H

AU - Easton, Alistair

AU - Roxburgh, Jennifer

AU - Pediani, John

AU - Furukawa, Koichi

AU - Furukawa, Keiko

AU - Goodyear, Carl S

AU - Plomp, Jaap J

AU - Willison, Hugh J

PY - 2009/3/2

Y1 - 2009/3/2

N2 - Anti-GM1 ganglioside autoantibodies are used as diagnostic markers for motor axonal peripheral neuropathies and are believed to be the primary mediators of such diseases. However, their ability to bind and exert pathogenic effects at neuronal membranes is highly inconsistent. Using human and mouse monoclonal anti-GM1 antibodies to probe the GM1-rich motor nerve terminal membrane in mice, we here show that the antigenic oligosaccharide of GM1 in the live plasma membrane is cryptic, hidden on surface domains that become buried for a proportion of anti-GM1 antibodies due to a masking effect of neighboring gangliosides. The cryptic GM1 binding domain was exposed by sialidase treatment that liberated sialic acid from masking gangliosides including GD1a or by disruption of the live membrane by freezing or fixation. This cryptic behavior was also recapitulated in solid-phase immunoassays. These data show that certain anti-GM1 antibodies exert potent complement activation-mediated neuropathogenic effects, including morphological damage at living terminal motor axons, leading to a block of synaptic transmission. This occurred only when GM1 was topologically available for antibody binding, but not when GM1 was cryptic. This revised understanding of the complexities in ganglioside membrane topology provides a mechanistic account for wide variations in the neuropathic potential of anti-GM1 antibodies.

AB - Anti-GM1 ganglioside autoantibodies are used as diagnostic markers for motor axonal peripheral neuropathies and are believed to be the primary mediators of such diseases. However, their ability to bind and exert pathogenic effects at neuronal membranes is highly inconsistent. Using human and mouse monoclonal anti-GM1 antibodies to probe the GM1-rich motor nerve terminal membrane in mice, we here show that the antigenic oligosaccharide of GM1 in the live plasma membrane is cryptic, hidden on surface domains that become buried for a proportion of anti-GM1 antibodies due to a masking effect of neighboring gangliosides. The cryptic GM1 binding domain was exposed by sialidase treatment that liberated sialic acid from masking gangliosides including GD1a or by disruption of the live membrane by freezing or fixation. This cryptic behavior was also recapitulated in solid-phase immunoassays. These data show that certain anti-GM1 antibodies exert potent complement activation-mediated neuropathogenic effects, including morphological damage at living terminal motor axons, leading to a block of synaptic transmission. This occurred only when GM1 was topologically available for antibody binding, but not when GM1 was cryptic. This revised understanding of the complexities in ganglioside membrane topology provides a mechanistic account for wide variations in the neuropathic potential of anti-GM1 antibodies.

KW - animals

KW - monoclonal antibodies

KW - autoantibodies

KW - axons

KW - G(M1) ganglioside

KW - glycolipids

KW - humans

KW - mice

KW - motor neurons

KW - nerve endings

KW - neuromuscular junction

KW - oligosaccharides

KW - peripheral nervous system diseases

KW - synaptic transmission

KW - ran GTP-binding protein

U2 - 10.1172/JCI37338

DO - 10.1172/JCI37338

M3 - Article

VL - 119

SP - 595

EP - 610

JO - Journal of Clinical Investigation

T2 - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -